Radialis
Thunder Bay · Founded 2016
About Radialis
Developer of an organ-targeted positron emission tomography (PET) imaging system designed for high-definition and low-dose applications in oncology, neurology, and cardiology. The company's technology has ten times the efficiency for detecting radiotracer compared to traditional PET systems. The system has broad FDA clearance in the U.S. for imaging and measuring injected positron emitting radiopharmaceuticals. The current leading (reimburseable) indication is high resolution imaging of primary solid tumors for treatment planning, particularly as an adjunct to traditional staging PET/CT without additional radiotracer. The company is also pursuing targeted early detection of cancer and Alzheimer's disease with low-dose imaging in high-risk populations.
Company Facts
- Founded: 2016
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.5M
- Funding stage: Seed
- Last round: Grant (Jul 2024)
- Website: http://www.radialis.com/
- Phone: 1-800-601-3177
Industries & Categories
Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/radialis-32559 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.